Synbio International, Inc. (SYIN)
| Market Cap | 190.43K -73.1% |
| Revenue (ttm) | n/a |
| Net Income | -471.10K |
| EPS | -0.00 |
| Shares Out | 476.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 285,660 |
| Open | 0.0003 |
| Previous Close | 0.0004 |
| Day's Range | 0.0003 - 0.0004 |
| 52-Week Range | 0.0002 - 0.0040 |
| Beta | -7.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Synbio International
Synbio International, Inc. engages in the development and clinical validation of artificial intelligence-based medical technologies to enhance diagnostic accuracy and improve patient outcomes. It also markets nutraceutical products that support long-term health, wellness, and disease management. The company was formerly known as Natural Harmony Foods, Inc. and changed its name to Synbio International, Inc. in July 2024. Synbio International, Inc. was incorporated in 2002 and is based in Sheridan, Wyoming. [Read more]
Financial Performance
Financial StatementsNews
Synbio (OTC: SYIN) Outlines a Two-Engine Healthcare Growth Strategy Combining Nutraceuticals and AI-Powered Mental Health Screening
Commercial launch underway through exclusive U.S. and Canada licensing deal; FacialDx NIMS™ clinical program advances toward Australian feasibility study; Company pursuing clinical funding structure d...
Synbio International Signs Exclusive Licensing Agreement for Proprietary Nutraceutical Products, Accelerating Path to Revenue
Partnership with MD PHD Wellness Establishes a Long-Term Product Pipeline; Flagship Formulation to Be Marketed Under Synbio's Healing Force™ Brand NEW YORK, NY – TheNewswire - Sept. 8, 2026 – Synbio I...
Synbio International Commences Revenue-Generating Operations With Launch of Healing Force™ Nutraceutical Division
Company Begins Executing Revenue Generation Strategy through First Commercial Product Launch New York, NY – Aug. 11, 2026 – TheNewswire – Synbio International, Inc. (OTC: SYIN) today marks a significa...
Synbio International Secures DWAC and DRS Eligibility
Modernized trading structure enables faster trading and broader market access New York, NY – TheNewswire - April 8, 2026 – Synbio International Inc. (OTC: SYIN) today announced that the Company has b...
Synbio Signs Agreement for a Proof-of-Concept Clinical Trial to Evaluate a Unique AI-Based Facial Analysis Screening Software for Mental Health Disorders
Synbio has signed a Master Services Agreement with a leading Australian clinical research organization, CRO Services Pty Ltd, a wholly owned subsidiary of ASX-listed Resonance Health Ltd (ASX: RHT). ...
Synbio International Inc. Expands Board and Strengthens Leadership with Appointment of Chief Financial Officer Ms. Desiree Cain, CPA, MBA
Strategic appointment underscores Synbio's commitment to financial excellence, governance, and shareholder value NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Synbio International Inc. (OTC: SYIN) (“Syn...